Hematologic Oncology | Specialty

Daratumumab Produces Dramatic Responses in Relapsed Light Chain Amyloidosis

September 12th 2016

Almost 90% of patients with previously treated light chain amyloidosis responded to single-agent daratumumab (Darzalex).

Clinicians, Researchers Continue Search for Better MDS/MPN Therapy

September 9th 2016

Diagnostic criteria and therapeutic strategies for myelodysplastic and myeloproliferative neoplasms continue to evolve as molecular and genetic studies have provided new insights into the diseases.

Exploring Lenalidomide Potential for Cure in 5q-Deletion MDS

September 8th 2016

Clinical experience with lenalidomide (Revlimid) in myelodysplastic syndromes has provided evidence of potential to improve survival and reduce the leukemic progression in patients with 5q-deletion.

Dr. Donnellan on TFR in Patients With CML Treated With Nilotinib

September 7th 2016

William B. Donnellan, MD, investigator, Hematologic Malignancies, principal investigator, Sarah Cannon Research Institute, discusses preliminary results of the ENESTop study, which looked at treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase who were treated with second-line nilotinib (Tasigna).

FDA Approves Blinatumomab for Pediatric Acute Lymphoblastic Leukemia

September 2nd 2016

The FDA has granted an accelerated approval to blinatumomab (Blincyto) for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Venetoclax Shows Single-Agent Activity in AML

August 16th 2016

Treatment with single-agent BCL-2 inhibitor venetoclax demonstrated an overall response rate of 19% with a tolerable safety profile in patients who were unfit for intensive chemotherapy for those with relapsed/refractory acute myeloid leukemia.

FDA Grants Pracinostat Breakthrough Designation for AML

August 2nd 2016

The FDA has granted pracinostat a breakthrough therapy designation for use in combination with azacitidine as a treatment for patients with newly diagnosed acute myeloid leukemia who are aged ≥75 years or ineligible for intensive chemotherapy.

Brentuximab Vedotin Shows Significant Clinical Activity in Phase III CTCL Trial

August 1st 2016

Brentuximab vedotin (Adcetris) significantly improved the rate of responses lasting at least 4 months in patients with CD-30­–positive cutaneous T-cell lymphoma, meeting the primary endpoint of the phase III ALCANZA trial.

Martin Moorhead on Role of Minimal Residual Disease in Leukemia and Lymphoma

July 29th 2016

Dr. Raoul Tibes Discusses FLT3 Inhibitors in AML

July 29th 2016

Dr. Lancet on CPX-351 in Elderly Patients With AML

July 28th 2016

Jeffrey E. Lancet, MD, medical oncologist, Moffitt Cancer Center, discusses results of a randomized phase III study comparing the efficacy of CPX-351 (Vyxeos) versus daunorubicin (7+3) plus cytarabine in older patients with newly diagnosed, high-risk acute myeloid leukemia (AML).

Dr. Max Topp on the TOWER study and Blinatumomab in ALL

July 28th 2016

Dr. Igor Aurer on Novel Treatments on the Horizon in Hodgkin Lymphoma

July 27th 2016

Dr. DeAngelo on Inotuzumab Ozogamicin for Relapsed/Refractory ALL

July 26th 2016

Dr. Younes Discusses FDA Approval of Nivolumab in Hodgkin Lymphoma

July 25th 2016

Anas Younes, MD, chief of the Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the impact of the FDA approval of nivolumab (Opdivo) for the treatment of patients with classical Hodgkin lymphoma.

Where Immuno-Oncology Is Heading

July 20th 2016

Brentuximab Vedotin in Advanced Lymphoid Malignancies

July 20th 2016

Anti-CD20 Antibodies for Advanced Hematologic Malignancies

July 20th 2016

Obinutuzumab for Indolent Lymphoma

July 20th 2016

Immunochemotherapy for Lymphoma

July 20th 2016